Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 10, 2024

Primary Completion Date

June 10, 2026

Study Completion Date

July 1, 2027

Conditions

T-LGL LeukemiaNK-LGL Leukemia

Interventions

DRUG

Thalidomide and methotrexate

Thalidomide at a dose of 50-100 mg/QN, Methotrexate 10 mg/m2 orally once a week.

Trial Locations (1)

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER